removed Category:Piperidines; added Category:1-Piperidinyl compounds using HotCat
|
Linked Pitolisant to wikipedia
Tags: Visual edit Mobile edit Mobile web edit
|
||
Line 90: | Line 90: | ||
}} |
}} |
||
'''Pitolisant''', sold under the brand name '''Wakix''' among others, is a [[medication]] for the treatment of [[excessive daytime sleepiness]] in adults with [[narcolepsy]].<ref name="Wakix FDA label" /> It is a [[Histamine H3 receptor|histamine 3 (H<sub>3</sub>) receptor]] antagonist/[[inverse agonist]].<ref name="Wakix FDA label">{{cite web | title=Wakix- pitolisant hydrochloride tablet, film coated | website=DailyMed | date=6 November 2019 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8daa5562-824e-476c-9652-26ceef3d4b0e | access-date=18 August 2020}}</ref> It represents the first commercially available medication in its class.<ref>{{cite web |title=FDA Approves Pitolisant for Daytime Sleepiness in Patients with Narcolepsy |url=https://www.pharmacytimes.com/news/fda-approves-pitolisant-for-daytime-sleepiness-in-patients-with-narcolepsy |website=Pharmacy Times |access-date=18 August 2020}}</ref> Pitolisant enhances the activity of histaminergic [[neurons]] in the brain that function to improve a person's wakefulness.<ref name="Syed Review">{{cite journal |vauthors=Syed YY |title=Pitolisant: First Global Approval |journal=Drugs |date=20 July 2016 |volume=76 |issue=13 |pages=1313–1318 |doi=10.1007/s40265-016-0620-1|pmid=27438291 |s2cid=42684839 }}</ref> |
'''[[Pitolisant]]''', sold under the brand name '''Wakix''' among others, is a [[medication]] for the treatment of [[excessive daytime sleepiness]] in adults with [[narcolepsy]].<ref name="Wakix FDA label" /> It is a [[Histamine H3 receptor|histamine 3 (H<sub>3</sub>) receptor]] antagonist/[[inverse agonist]].<ref name="Wakix FDA label">{{cite web | title=Wakix- pitolisant hydrochloride tablet, film coated | website=DailyMed | date=6 November 2019 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8daa5562-824e-476c-9652-26ceef3d4b0e | access-date=18 August 2020}}</ref> It represents the first commercially available medication in its class.<ref>{{cite web |title=FDA Approves Pitolisant for Daytime Sleepiness in Patients with Narcolepsy |url=https://www.pharmacytimes.com/news/fda-approves-pitolisant-for-daytime-sleepiness-in-patients-with-narcolepsy |website=Pharmacy Times |access-date=18 August 2020}}</ref> Pitolisant enhances the activity of histaminergic [[neurons]] in the brain that function to improve a person's wakefulness.<ref name="Syed Review">{{cite journal |vauthors=Syed YY |title=Pitolisant: First Global Approval |journal=Drugs |date=20 July 2016 |volume=76 |issue=13 |pages=1313–1318 |doi=10.1007/s40265-016-0620-1|pmid=27438291 |s2cid=42684839 }}</ref> |
||
The most common side effects include difficulty sleeping, nausea, and feeling worried.<ref name="FDA snapshot" /> |
The most common side effects include difficulty sleeping, nausea, and feeling worried.<ref name="FDA snapshot" /> |
![]() | |
Clinical data | |
---|---|
Trade names | Wakix, Ozawade |
Other names | Tiprolisant; Ciproxidine; BF2.649 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a619055 |
License data |
|
Routes of administration | By mouth |
Drug class | Histamine H3 receptor inverse agonists |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
![]() |
PubChem CID | |
DrugBank |
|
ChemSpider |
|
UNII |
![]() |
KEGG |
![]() |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H26ClNO |
Molar mass | 295.85 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Pitolisant, sold under the brand name Wakix among others, is a medication for the treatment of excessive daytime sleepiness in adults with narcolepsy.[2] It is a histamine 3 (H3) receptor antagonist/inverse agonist.[2] It represents the first commercially available medication in its class.[5] Pitolisant enhances the activity of histaminergic neurons in the brain that function to improve a person's wakefulness.[6]
The most common side effects include difficulty sleeping, nausea, and feeling worried.[7]
The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[8]
Pitolisant (Wakix) is used in adults for the treatment of excessive daytime sleepiness and narcolepsy.[2][3] Narcolepsy is a sleep problem that is characterized by an irresistible urge to sleep and disturbed nighttime sleep, while cataplexy refers to attacks of severe muscle weakness that cause a person to collapse.[3] Pitolisant (Ozawade) is indicated to improve wakefulness and reduce excessive daytime sleepiness in adults with obstructive sleep apnea.[4]
The most common side effects include insomnia (difficulty sleeping), headache, nausea (feeling sick), anxiety, irritability, dizziness, depression, tremor, sleep disorders, tiredness, vomiting, vertigo (a spinning sensation) and dyspepsia (heartburn).[3] Serious but rare side effects are abnormal loss of weight and spontaneous abortion.[3]
Pitolisant was developed by Jean-Charles Schwartz, Walter Schunack, and colleagues after the former discovered the H3 receptor.[9] It was the first H3 receptor inverse agonist to be tested in humans or introduced for clinical use.[9] It is marketed in the European Union by Bioprojet Pharma.[3] It was approved for medical use in the European Union in March 2016.[3]
The FDA approved pitolisant for excessive daytime sleepiness in participants with narcolepsy based primarily on evidence from two trials (Trial 1/NCT01067222, Trial 2/NCT01638403).[7] An additional trial (Trial 3/NCT01800045), in which participants with a different type of narcolepsy were exposed to the same dose of pitolisant, was used to add data for evaluation of side effects.[7] The trials were conducted in Europe and South America.[7]
The two primary trials enrolled adults with narcolepsy and excessive daytime sleepiness.[7] Participants received pitolisant, placebo, or an approved drug for narcolepsy for eight weeks.[7] For participants receiving pitolisant, the dose could be increased during the first three weeks but had to remain the same for the next five weeks.[7] Neither the participants nor the healthcare providers knew which treatment was being given during the trial.[7]
The benefit of pitolisant was evaluated by comparing changes in daytime sleepiness during the trial between pitolisant- and placebo-treated participants.[7] To measure the daytime sleepiness, the investigators used a scale called the Epworth Sleepiness Scale (ESS).[7] The ESS asks participants to rate the likelihood that they would fall asleep while doing eight daily activities (such as sitting and reading or watching television).[7] Participants rate each item from zero (would never doze) to three (high chance of dozing).[7]
Pitolisant was approved by the U.S. Food and Drug Administration (FDA) in August 2019.[7] It was granted orphan drug designation for the treatment of narcolepsy,[10] fast track designation for the treatment of excessive daytime sleepiness and cataplexy in people with narcolepsy, and breakthrough therapy designation for the treatment of cataplexy in people with narcolepsy.[11]
![]() | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |